Literature DB >> 27511715

Stereotactic Radiosurgery for Treatment of Brain Metastases.

Shahed N Badiyan1, William F Regine1, Minesh Mehta2.   

Abstract

Brain metastases are the most common intracranial malignancy. Incidence of brain metastases has risen as systemic therapies have improved and patients with metastatic disease live longer. Whole-brain radiation therapy, for many years, has been the standard treatment approach. Stereotactic radiosurgery has become an increasingly popular option because of its relatively short, convenient, and noninvasive treatment course. Although recently published data have renewed interest in use of whole-brain radiation therapy or systemic therapies for control of micrometastatic disease, stereotactic radiosurgery continues to be an important modality, capable of delivering ablative doses of radiation for long-term control of macroscopic disease. The purpose of this review is to explore the different paradigms for incorporation of stereotactic radiosurgery into management of brain metastases. Current uses for stereotactic radiosurgery include delivery as a boost with whole-brain radiation therapy; alone for patients with a limited number of brain metastases; in pre- or postoperative settings; and in combination with systemic, targeted, and immune-based therapies. Mature prospective data on use of stereotactic radiosurgery in combination with whole-brain radiation therapy is available; however, prospective, randomized data on stereotactic radiosurgery for patients with a greater number of brain metastases, its use in pre- and postoperative settings, and its use in combination with systemic therapies are limited. Data from ongoing and future studies are needed to define the appropriate use of stereotactic radiosurgery in these settings.
Copyright © 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27511715     DOI: 10.1200/JOP.2016.012922

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  19 in total

1.  Improving outcomes for brain metastases in EGFR mutated NSCLC.

Authors:  Jennifer W Carlisle; Suresh S Ramalingam
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.

Authors:  Mario Muto; Giulia Frauenfelder; Rossana Senese; Fabio Zeccolini; Emiliano Schena; Francesco Giurazza; Hans Rolf Jäger
Journal:  Radiol Med       Date:  2018-03-05       Impact factor: 3.469

3.  Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery.

Authors:  Carmine Antonio Donofrio; Andrea Cavalli; Marco Gemma; Lucia Riccio; Alessandra Donofrio; Pietro Panni; Camillo Ferrari da Passano; Antonella Del Vecchio; Angelo Bolognesi; Riccardo Soffietti; Pietro Mortini
Journal:  Clin Exp Metastasis       Date:  2020-05-19       Impact factor: 5.150

4.  The effect of MLC leaf width in single-isocenter multi-target radiosurgery with volumetric modulated arc therapy.

Authors:  Zhanerke Abisheva; Scott R Floyd; Joseph K Salama; John Kirkpatrick; Fang-Fang Yin; Michael J Moravan; William Giles; Justus Adamson
Journal:  J Radiosurg SBRT       Date:  2019

Review 5.  Brain metastases: An update on the multi-disciplinary approach of clinical management.

Authors:  D K Mitchell; H J Kwon; P A Kubica; W X Huff; R O'Regan; M Dey
Journal:  Neurochirurgie       Date:  2021-04-14       Impact factor: 1.553

6.  Neuroinflammation After Stereotactic Radiosurgery-Induced Brain Tumor Disintegration Is Linked to Persistent Cognitive Decline in a Mouse Model of Metastatic Disease.

Authors:  Chengyan Chu; Catherine M Davis; Xiaoyan Lan; Robert D Hienz; Anna Jablonska; Aline M Thomas; Esteban Velarde; Shen Li; Miroslaw Janowski; Mihoko Kai; Piotr Walczak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-26       Impact factor: 7.038

Review 7.  Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Peng Yuan; Song-Lin Gao
Journal:  Chronic Dis Transl Med       Date:  2017-03-08

Review 8.  Brain Metastasis Organotropism.

Authors:  Arseniy E Yuzhalin; Dihua Yu
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

Review 9.  Sociodemographic disparities in the management of advanced lung cancer: a narrative review.

Authors:  Jacob Newton Stein; M Patricia Rivera; Ashley Weiner; Narjust Duma; Louise Henderson; Gita Mody; Marjory Charlot
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 3.005

10.  Practical consensus recommendations on Her2 +ve breast cancer with solitary brain mets.

Authors:  Nitesh Rohatgi; A Munshi; P Bajpai; M Singh; S Sahai; M Ahmad; K Singh; H Singh; Purvish M Parikh; S Aggarwal
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.